Navigation Links
XK-95 High Speed Drill System

ProductsXK-95 High Speed Drill System
Company Brasseler USA
Item XK-95 High Speed Drill System
Features Combines precision, ultra-high speed and excellent feedback to provide the surgeon with instrumentation that flawlessly performs under the most exacting conditions. From the lightweight, ergonomic design of the hand piece, to its efficient, tool-less quickconnections, the XK-95 High Speed Drill System incorporates all the advanced features that todays surgeon demands. The XK-95 is a pneumatic, micromotor system developed for the rapid dissection of bone, bioplastics, biometals and cement. It is becoming the High Speed Drill System of choice for neuro, orthopedic, and ENT surgery. Highly versatile, the XK-95 system was designed to accommodate all procedures where high-speed dissection is required.
Description The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems.
Info Brasseler USA
Customer Service: (800) 535-6638
Web site: http://www.brasselerusamedical.com/

Related medicine products :

1. GR 20.22 Compact High Speed Refrigerated Floor-Standing Centrifuge
2. MR 23 Multi-Function Programmable High and Low Speed Refrigerated Centrifuge.
3. KR 22i High Speed Refrigerated Floor-Standing Centrifuge.
4. XK-PRO 100 High Speed Drill System
5. Hilan High Speed Drill System
6. Hilan XS High Speed Drill System
7. HeartSpeed HB Bi-plane Cardiac System
8. AngioSpeed H series
9. AngioSpeed V series
10. AngioSpeed VH
11. eSpeed C300 EBT
Straight Tissue Forceps
Sanders-Castroviejo Suturing Forceps
Storz Bonn Suturing Forceps
Berens Curved Suturing Forceps
Medicine Products:
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...ing based on the ‘survival of the fittest’ theory,...a motive to nurture// the healthy ones, has borne ...ple, the first in UK, after successfully employing...y prone to a condition called cystic fibrosis, a g...
... choice for treatment of influenza is causing pand...sychiatric// side effects, regulators said today. ...fter series of cases of self-injury and mental dis...l approved by U.S FDA cautions medical practitione...
...utt and Yujiang Song from Sandia National Laborat... how a drug attaches //to a cell which involves a ...ctures. Sandia is a National Nuclear Security Admi... currently published the same as an advance public...
...s may do little to improve the use of continuous p...th obstructive sleep apnea (OSA). A new study publ...iewed journal of the American College of Chest Phy...OSA taking a placebo. “CPAP treatment improve...
... and a half years old, is reported to have died fr...spital on Sunday. //The toddler from West Java pro...estic fowl. With this, the death toll, due to this... not related. Most of those affected have caug...
...an opportune time to evaluate the support availabl...orld coping with a galloping disease. Taking// cog...06 - 'Diabetes Care for Everyone, especially the d...w attention towards the communities and groups in ...
Other Medicine News:Health News:Caution:Tamiflu ‘tames’ flu but psychiatric side effects now report 2Health News:Novel methods to view how a drug attaches to a cell 2Health News:Research Questions Use of Sleep Meds for Patients with Apnea 2Health News:The Holy Grail of Diabetes Management 2Health News:The Holy Grail of Diabetes Management 3
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers of the AcceleDent System , which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Oncolytics Biotech 28R 29 Inc Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 14749 1Oncolytics Biotech 28R 29 Inc Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 14749 2Oncolytics Biotech 28R 29 Inc Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 14749 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 6055 1Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 6055 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 6053 1NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 6053 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 6053 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 6053 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 6053 5